Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4017244 | 0.85 | PDGFRB (0.44) | ALDH1A1PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL2522874 | 0.85 | PDGFRB (0.47) | ALDH1A1LMNAPDGFRBFGFR1PDGFRA | |
| SCHEMBL913705 | 0.84 | PDGFRB (0.46) | ALDH1A1PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL2046728 | 0.84 | PDGFRB (0.49) | ALDH1A1LMNAPDGFRBFGFR1PDGFRA | |
| SCHEMBL4022732 | 0.84 | PDGFRB (0.46) | ALDH1A1PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL31159174 | 0.84 | PDGFRB (0.49) | ALDH1A1LMNAPDGFRBFGFR1PDGFRA | |
| SCHEMBL29858635 | 0.83 | TTR (0.50) | ALDH1A1LMNAPDGFRBFGFR1PDGFRA | |
| SCHEMBL205671 | 0.83 | TTR (0.50) | ALDH1A1LMNAPDGFRBFGFR1PDGFRA | |
| SCHEMBL505591 | 0.83 | PDGFRB (0.48) | ALDH1A1LMNAPDGFRBFGFR1PDGFRA | |
| SCHEMBL221958 | 0.83 | ALDH1A1 (0.46) | ALDH1A1LMNAPDGFRBFGFR1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025023769-A1 | NOVEL SYNTHESIS METHOD OF 18F-RUCAPARIB | 고려대학교 산학협력단 | 2025-01-30 | — | — | WO | disclosed |
| EP-3585772-B1 | 1, 4, 6-TRISUBSTITUTED-2-ALKYL-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | MERCK PATENT GMBH (DE) | 2023-10-11 | — | — | EP | disclosed |
| CN-107922430-B | 2-substituted benzimidazole-4-formamide compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2020-09-04 | — | — | CN | disclosed |
| US-10196381-B2 | Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition containing the same, preparation method and use thereof | SHANGHAI HUILUN LIFE SCIENCE &TECHNOLOGY CO., LTD (CN) | 2019-02-05 | — | — | US | disclosed |
| EP-3012256-B1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECH CO LTD (CN) | 2018-08-08 | — | — | EP | disclosed |
| US-20160159776-A1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2016-06-09 | — | — | US | disclosed |
| US-20160159776-A1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2016-06-09 | — | — | US | disclosed |
| US-20160159776-A1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2016-06-09 | — | — | US | disclosed |
| EP-3012256-A1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD AND USE THEREOF | Shanghai Huilun Life Science & Technology Co., Ltd (CN) | 2016-04-27 | — | — | EP | disclosed |
| EP-3012256-A1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD AND USE THEREOF | Shanghai Huilun Life Science & Technology Co., Ltd (CN) | 2016-04-27 | — | — | EP | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| WO-2014201972-A1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD AND USE THEREOF | 上海汇伦生命科技有限公司 (CN) | 2014-12-24 | — | — | WO | disclosed |
| EP-2414328-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Merck Serono S.A. (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| WO-2010115736-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| EP-1208104-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMA (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6548494-B1 | 3,4-dihydro-2H-(1,4)diazepino(6,7,1-hi)indol-1-one or 1-thione derivatives where indole C3 could also be N; use treating cancers as well as stroke, head trauma, and neurodegenerative diseases | AGOURON PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| EP-1208104-A2 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001016136-A2 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159776-A1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PREPARATION METHOD AND USE THEREOF | PARP2, PARP1, PARP15 | ALDH1A1 231/4885LMNA 838/4885PDGFRB 76/4885 |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, FH, DPYD | ALDH1A1 95/4885LMNA 4317/4885PDGFRB 4173/4885 |
| US-10196381-B2 | Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition containing the same, preparation method and use thereof | PARP2, PARP1, PARP15 | ALDH1A1 231/4885LMNA 838/4885PDGFRB 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.